Statin treatment in hypercholesterolemic men does not attenuate angiotensin ii-induced venoconstriction

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Schindler, Christoph ^a,b,d   Guenther, Kristina ^b,d   Hermann, Cosima ^b,d   Ferrario, Carlos M ^c,d   Schroeder, Christoph ^a,d   Haufe, Sven ^a,d   Jordan, Jens ^a,d   Kirch, Wilhelm ^b,d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Departments of Surgery Internal Medicine Nephrology Physiology Pharmacology   (Germany)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN[1-7]; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN;

ADULT; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; MALE; RANDOMIZED CONTROLLED TRIAL; VENOCONSTRICTION; BLOOD; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASOCONSTRICTION; VEIN;

ANGIOTENSIN II; DOUBLE-BLIND METHOD; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; VASOCONSTRICTION; VEINS;

EID: 84907494659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103909     Document Type: Article

References (32)

1. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, et al. (1999) Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100: 2131-2134
2. Maczewski M, Maczewska J, Duda M (2008) Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors. Br J Pharmacol 154: 1640-1648
3. Strehlow K, Wassmann S, Bohm M, Nickenig G (2000) Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med 32: 386-389
4. Dechend R, Fiebler A, Lindschau C, Bischoff H, Muller D, et al. (2001) Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens 14: 55S-61S
5. Sim JS, Dick JB, Struthers AD (2004) Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients. J Renin Angiotensin Aldosterone Syst 5: 109-113
6. Jordan J, Tank J, Shannon JR, Diedrich A, Lipp A, et al. (2002) Baroreflex buffering and susceptibility to vasoactive drugs. Circulation 105: 1459-1464
7. Schindler C, Brosnihan KB, Ferrario CM, Bramlage P, Maywald U, et al. (2007) Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. J Clin Pharmacol 47: 112-120
8. Goldberg MR, de Mey C, Wroblewski JM, Li Q, Schroeter V, et al. (1996) Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men. Clin Pharmacol Ther 59: 72-82
9. Harada K, Ohmori M, Fujimura A (2002) Vasoconstricting effect of angiotensin II in human hand veins: influence of aging, diabetes mellitus and hypertension. Hypertens Res 25: 683-688
10. Aguilar C, Ventura F, Rodriguez-Delfin L (2011) Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy. Rev Peru Med Exp Salud Publica 28: 264-272
11. Zhang C, Zhao YX, Zhang YH, Zhu L, Deng BP, et al. (2010) Angiotensinconverting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proceedings of the National Academy of Sciences of the United States of America 107: 15886-15891
12. Pang CC (2001) Autonomic control of the venous system in health and disease: effects of drugs. Pharmacol Ther 90: 179-230
13. Martin DS, Rodrigo MC, Appelt CW (1998) Venous tone in the developmental stages of spontaneous hypertension. Hypertension 31: 139-144
14. Tran D, Lowy A, Howes JB, Howes LG (2005) Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men. Diabetes Obes Metab 7: 273-281
15. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, et al. (1999) Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 33: 719-725
16. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, et al. (2001) HMGCoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37: 1450-1457
17. Nickenig G, Jung O, Strehlow K, Zolk O, Linz W, et al. (1997) Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol 272: H2701-2707
18. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, et al. (2001) Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 59: 646-654
19. Lee BH, Shin HS (1997) Interaction of nitric oxide and renin angiotensin system in pulmonary arterial circulation of RHR. Arch Pharm Res 20: 389-395
20. Toda N, Ayajiki K, Okamura T (2007) Interaction of endothelial nitric oxide and angiotensin in the circulation. Pharmacol Rev 59: 54-87
21. Grossmann M, Dobrev D, Siffert W, Kirch W (2001) Heterogeneity in hand veins responses to acetylcholine is not associated with polymorphisms in the Gprotein beta3-subunit (C825T) and endothelial nitric oxide synthase (G894T) genes but with serum low density lipoprotein cholesterol. Pharmacogenetics 11: 307-316
22. Murad F (1986) Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 78: 1-5
23. Schindler C, Leuschner S, Schwanebeck U, Kirch W (2012) Characterization of local vascular effects of the nitric oxide inhibitor NG-monomethyl-L-arginine on dorsal hand veins. J Clin Pharmacol 52: 859-869
24. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, et al. (2007) Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49: 185-192
25. Durand MJ, Raffai G, Weinberg BD, Lombard JH (2010) Angiotensin-(1-7) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries. Am J Physiol Heart Circ Physiol 299: H1024-1033
26. Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, et al. (2010) Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 56: 112-120
27. Maia LG, Ramos MC, Fernandes L, de Carvalho MH, Campagnole-Santos MJ, et al. (2004) Angiotensin-(1-7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J Cardiovasc Pharmacol 43: 685-691
28. Collister JP, Hendel MD (2003) The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats. J Renin Angiotensin Aldosterone Syst 4: 176-179
29. Matsukawa T, Gotoh E, Minamisawa K, Kihara M, Ueda S, et al. (1991) Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol 261: R690-696
30. Moreira ED, Mostarda CT, Moraes-Silva IC, Ferreira JB, Dos Santos F, et al. (2013) Effect of simvastatin in the autonomic system is dependent on the increased gain/sensitivity of the baroreceptors. Physiol Rep 1: e00045
31. Kishi T, Hirooka Y, Konno S, Sunagawa K (2009) Atorvastatin improves the impaired baroreflex sensitivity via anti-oxidant effect in the rostral ventrolateral medulla of SHRSP. Clin Exp Hypertens 31: 698-704
32. Wang WZ, Gao L, Pan YX, Zucker IH, Wang W (2007) AT1 receptors in the nucleus tractus solitarii mediate the interaction between the baroreflex and the cardiac sympathetic afferent reflex in anesthetized rats. Am J Physiol Regul Integr Comp Physiol 292: R1137-1145